Detailed explanation of possible side effects of atezolizumab subcutaneous preparation (TECENTRIQ HYBREZA)

Atezolizumab subcutaneous preparation is a combination preparation composed of programmed death ligand 1 (PD-L1) monoclonal antibody and recombinant human hyaluronidase (rHuPH20). It has been used to treat a variety of solid tumor types including non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma and alveolar soft tissue sarcoma. As a delivery method for immune checkpoint inhibitors, atezolizumab subcutaneous preparations have certain advantages in improving treatment compliance and shortening infusion time. However, they are also accompanied by a series of side effects related to immune mechanisms, which need to be paid attention to in clinical use.

The most common adverse reactions to subcutaneous atezolizumab when used to treat non-small cell lung cancer are general fatigue or weakness, musculoskeletal pain, persistent cough, shortness of breath, and decreased appetite. Although these symptoms are not necessarily severe, they may affect the patient's quality of daily life. In addition, multi-system reactions such as rash, headache, nausea, hypertension, vomiting, constipation, dizziness, bleeding tendencies, diarrhea, sleep disorders, gastric and abdominal pain, hypothyroidism, fever, anxiety, abnormal heart rhythm, numbness and pain in the limbs, hair loss, elevated urine protein, abnormal liver function, oral mucosal ulcers, photosensitivity reactions, limb edema, and itching may also be observed with or without combination with other anti-tumor drugs. Although most of these reactions are mild to moderate, if they persist or gradually worsen, they may indicate more serious immune-related complications.

Of particular concern are the serious immune-mediated side effects caused by the subcutaneous formulation of atezolizumab. Since the mechanism of action of this drug is to relieve the suppression of the immune system by tumors and activate T cells to recognize and eliminate cancer cells, while enhancing the anti-tumor immune response, it may also trigger the body's immune system to mistakenly attack normal tissues, leading to damage to multiple organ systems including the lungs, intestines, liver, endocrine glands, kidneys, skin and nervous system.

In the lungs, common symptoms include cough, chest pain and dyspnea, so we need to be alert to immune-related pneumonia. In the intestinal system, it may cause immune colitis, manifesting as diarrhea or bloody stools. Liver damage is often preceded by jaundice, elevated transaminases, or right upper quadrant pain. Endocrine abnormalities may affect pituitary, thyroid or adrenal function, with specific manifestations including headaches, fatigue, appetite changes, personality changes, cold intolerance, or abnormal weight changes. Kidney problems such as proteinuria or reduced kidney function may progress to immune nephritis, with decreased urine output, blood in the urine, or edema of the legs. Skin conditions include severe rashes, blisters, peeling, and even mucosal damage. Although neurological adverse reactions are uncommon, once they occur, such as emotional confusion, cognitive impairment, movement disorders, vision changes, etc., the drug should be stopped immediately and high-intensity immunosuppressive treatment should be initiated.

In addition, you need to be alert to infusion reactions, which may include chills, itching, rash, facial flushing, difficulty breathing, hypotension, dizziness or back pain. In rare cases, it may even progress to anaphylactic shock. For patients who have received hematopoietic stem cell transplantation, subcutaneous formulations of atezolizumab may cause graft-versus-host disease (GVHD), which can be rapidly progressive and life-threatening.

Therefore, during the treatment process, doctors will regularly monitor indicators including liver and kidney function, electrolytes, thyroid hormone levels, and complete blood cell counts, and conduct timely clinical assessments based on the patient's chief complaints. Once a suspected immune-related adverse event occurs, the severity should be promptly assessed and immunosuppressive therapy, including corticosteroids, initiated. If side effects cannot be controlled, treatment may need to be discontinued temporarily or permanently.

To sum up, although the side effects of atezolizumab subcutaneous preparation as an immunotherapy method are controllable to a certain extent, they cannot be ignored. During clinical use, monitoring and patient education need to be strengthened to ensure that immune-related damage is avoided as much as possible while benefiting, and treatment safety is optimized.

Reference: https://www.drugs.com/search.php?searchterm=TECENTRIQ+HYBREZA